Trials / Terminated
TerminatedNCT00912054
DuoTrav APS Versus XALACOM® in Ocular Surface Health
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 240 (actual)
- Sponsor
- Alcon Research · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To demonstrate superiority of DuoTrav APS over XALACOM® in Ocular Surface Health in patients with open angle glaucoma or ocular hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DuoTrav APS | travoprost APS 40 micrograms/ml / timolol 5 mg/ml, Eye Drops, Solution, once daily |
| DRUG | Xalacom | XALACOM® (latanoprost 50 micrograms/ml / timolol 5 mg/ml) Eye Drops, Solution |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2011-05-01
- Completion
- 2011-05-01
- First posted
- 2009-06-03
- Last updated
- 2012-07-19
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT00912054. Inclusion in this directory is not an endorsement.